Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 11 I, 2005, Pages 2509-2516

  Ulrich, Cornelia M ^a   Curtin, Karen ^b   Potter, John D ^a   Bigler, Jeannette ^a   Caan, Bette ^c   Slattery, Martha L ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHIONINE SYNTHASE; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COLON CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENHANCER REGION; ENZYME ACTIVITY; FEMALE; FOLATE METABOLISM; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VITAMIN INTAKE; WILD TYPE;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADENOMA; ADULT; AGED; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; DIET; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE;

EID: 28644446615     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0261     Document Type: Article

References (68)

1. Wagner C. Biochemical role of folate in cellular metabolism. Folate in health and disease. New York: Marcel Dekker; 1995.
2. World Cancer Research Fund. Diet, nutrition, and the prevention of cancer: a global perspective. Washington (DC): World Cancer Research Fund/American Institute for Cancer Research; 1997.
3. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002;132:2350-5S.
4. Marugame T, Tsuji E, Kiyohara C, et al. Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas [comment]. Int J Epidemiol 2003;32:64-6.
5. Pufulete M, Al-Ghnaniem R, Leather AJ, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003;124:1240-8.
6. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
7. Chen J, Giovannucci E, Hankinson SE, et al. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998;19:2129-32.
8. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999;8:513-8.
9. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999;8:659-68.
10. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002;62:3361-4.
11. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129-32.
12. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999;55:578-92.
13. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004;13:285-92.
14. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-7.
15. Ulrich C, Bigler J, Velicer C, Greene E, Farin F, Potter J. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9:1381-5.
16. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intrarumoral TS mRNA levels. Pharmacogenetics 2004;14:319-27.
17. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310-5.
18. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-4.
19. Leclerc D, Wilson A, Dumas R, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 1998;95:3059-64.
20. Chen J, Stampfer MJ, Ma J, et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001;154:667-72.
21. Harmon D, Shields D, Woodside J, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17:298-309.
22. Ma J, Stampfer MJ, Christensen B, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:825-9.
23. van der Put NM, van der Molen EF, Kluijtmans LA, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM 1997;90:511-7.
24. Jacques PF, Bostom AG, Selhub J, et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 2003;166:49-55.
25. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C → T and methionine synthase 2756A → G polymorphisms: a study of 2,168 case-control pairs from the JANUS Cohort. Cancer Epidemiol Biomarkers Prev 2004;13:2175-80.
26. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2004;13:157-62.
27. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Gen 1994;7:536-40.
28. Slattery ML, Edwards SL, Caan BJ, Kerber RA, Potter JD. Response rates among control subjects in case-control studies. Ann Epidemiol 1995;5:245-9.
29. Slattery ML, Caan BJ, Duncan D, Berry TD, Coates A, Kerber R. A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 1994;94:761-6.
30. Edwards S, Slattery ML, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994;140:1020-8.
31. Liu K, Slattery M, Jacobs D, Jr., et al. A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis 1994;4:15-27.
32. Kampman E, Slattery ML, Bigler J, et al. Meat consumption, genetic susceptibility, and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol Biomarkers Prev 1999;8:15-24.
33. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
34. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
35. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-6.
36. Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 2002;3:299-313.
37. Ulrich CM, Potter JD. Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil [comment]. Br J Cancer 2002;86:22.
38. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat Gen 1995;10:111-3.
39. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A 1998;95:13217-20.
40. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
41. Trinh BN, Ong C-N, Coetzee GA, Yu MC, Laird PW. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 2002;111:299-302.
42. Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001;7:3416-22.
43. Chen J, Hunter DJ, Stampfer MJ, et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003;12:958-62.
44. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301.
45. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002;13:239-48.
46. Quinlivan EP, Davis SR, Shelnutt KP, et al. Methylenetetrahydrofolate reductase 677C>T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynudeosides. J Nutr 2005;135:389-96.
47. Lindahl T, Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry 1972;11:3610-8.
48. Nakamura J, Swenberg JA. Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues. Cancer Res 1999;59:2522-6.
49. Antony AC. The biological chemistry of folate receptors. Blood 1992;79:2807-20.
50. van Baal WM, Smolders RG, van der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485-91.
51. Smolders RG, Vogelvang TE, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41:105-14.
52. Somekawa Y, Kobayashi K, Tomura S, Aso T, Hamaguchi H. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. Fertil Steril 2002;77:481-6.
53. Mijatovic V, van der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med 2001;39:764-7.
54. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
55. Issa JP. Opinion: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
56. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14 Spec No 1:R65-76.
57. Reed MC, Nijhout HF, Sparks R, Ulrich CM. A mathematical model of the methionine cycle. J Theor Biol 2004;226:33-43.
58. Nijhout HF, Reed MC, Budu P, Ulrich CM. A mathematical model of the folate cycle: new insights into folate homeostasis. J Biol Chem 2004;279:55008-16.
59. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:557-9.
60. Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004;104:2155-62.
61. Skibola CF, Smith MT, Hubbard A, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002;99:3786-91.
62. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999;96:12810-5.
63. Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A 2001;98: 4004-9.
64. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004;117:26-31.
65. O'Leary VB, Parle-McDermott A, Molloy AM, et al. MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet 2002;107:151-5.
66. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001;1:189-201.
67. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002;54:599-618.
68. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80:1611-7.